貝瑞基因(000710.SZ)擬受讓福建和瑞1.544%股權 持股將達20.956%
格隆匯2月14日丨貝瑞基因(000710.SZ)公佈,近日,公司子公司福建和瑞基因科技有限公司(以下簡稱“福建和瑞”)做出股東會決議,決議約定珠海思禮、珠海思義將其持有福建和瑞尚未履行完畢實繳出資義務合計6.176%股權無償轉讓給福建和瑞現有股東,該部分股權對應福建和瑞413.79萬元註冊資本,對應7000萬元實繳出資義務。
本次轉讓中,公司擬受讓珠海思禮、珠海思義合計轉讓的福建和瑞1.544%股權,該等股權對應福建和瑞103.448萬元註冊資本。本次交易完成後,公司將持有福建和瑞20.956%股權。
本次交易完成後,公司將向福建和瑞履行實繳出資義務,福建和瑞將繼續獲得發展腫瘤業務的資金保障;福建和瑞將繼續為公司參股子公司,公司將避免腫瘤業務大量研發投入產生的潛在風險,並在風險可控的條件下享受福建和瑞未來發展的收益,有利於保護中小股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.